Combined effect of factor V Leiden and prothrombin 20210A on the risk of venous thromboembolism: Pooled analysis of 8 case-control studies including 2310 cases and 3204 controls

Thrombosis and Haemostasis

Volumn 86, Issue 3, 2001, Pages 809-816

  Emmerich, J ^a   Rosendaal, F R ^a   Cattaneo, M ^a   Margaglione, M ^a   De Stefano, V ^a   Cumming, T ^a   Arruda, V ^a   Hillarp, A ^a   Reny, J L ^a  

^a HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

Deep vein thrombosis; Factor II G20210A; Factor V Leiden; Oral contraceptive

Indexed keywords

BLOOD CLOTTING FACTOR 5 LEIDEN; ORAL CONTRACEPTIVE AGENT; PROTHROMBIN;

ADULT; ARTICLE; CASE CONTROL STUDY; COMPARATIVE STUDY; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DISEASE ASSOCIATION; DRUG EFFECT; DRUG USE; FEMALE; GENE MUTATION; GENETIC ASSOCIATION; GENETIC RISK; HETEROZYGOSITY; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PRIORITY JOURNAL; THROMBOEMBOLISM;

EID: 0034840147     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1616136     Document Type: Article

References (44)

1. Risk factors for venous thrombotic disease
2. Role of hemostatic gene polymorphisms in venous and arterial thrombosis
3. Hereditary thrombophilia as a model for multigenic disease
4. Thrombophilia as a multigenic disorder
5. Risk factors for venous thrombosis: Prevalence, risk, and interaction
6. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C
7. Mutation in blood coagulation factor V associated with resistance to activated protein C
8. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis
9. World distribution of factor V Leiden
10. Venous thrombosis due to a poor anticoagulant response to activated protein C: Leiden Thrombophilia Study
11. Resistance to activated protein C as a basis for venous thrombosis
12. High risk of thrombosis in patients homozygous for factor V Leiden
13. Geographic distribution of the 20210 G to A prothrombin variant
14. The 20210A allele of the prothrombin gene is a common risk factor among Swedish outpatients with verified deep venous thrombosis
15. The prothrombin gene G20210A variant: Prevalence in a UK anticoagulant clinic population
16. Prevalence of the prothrombin gene variant (nt20210A) in venous thrombosis and arterial disease
17. Increased risk for venous thrombosis in carriers of the prothrombin G→A20210 gene variant
18. The G20210A mutation of the prothrombin genein patients with previous first episode of deep-vein thrombosis: Prevalence and association with factor V G1691A, methylenetetrahydrofolate reductase C677T and plasma prothrombin levels
19. Prevalence of the factor II G20210A mutation in symptomatic patients with inherited thrombophilia
20. Venous thromboembolic disease and the prothrombin, methylene tetrahydrofolate reductase and factor V genes
21. Risk of venous thromboembolism associated with a G to A transition at position 20210 in the 3′-untranslated region of the prothrombin gene
22. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation
23. Factor V Leiden paradox: Risk of deep-vein thrombosis but not of pulmonary embolism
24. Detection of factor V Leiden mutation using SSCP
25. Comparison of efficacy and safety of low molecular weight heparin and unfractionned heparin in initial treatment of deep venous thrombosis: A meta-analysis
26. EasyMA: A program for the meta-analysis of clinical trials
27. Interpretation of results from genetic studies of multifactorial diseases
28. Co-inheritance of the 20210A allele of the prothrombin gene increases the risk of thrombosis in subjects with familial thrombophilia
29. The prothrombin 20210 A allele is frequently coinherited in young carriers of the factor V Arg 506 to Gln mutation with venous thrombophilia
30. The A20210 allele of the prothrombin gene is frequently associated with the factor V Arg 506 to Gln mutation but not with protein S deficiency in thrombophilic families
31. The risk of recurrent deep venous thrombosis among heterozygous carriers of both factor V Leiden and the G20210A prothrombin mutation
32. Coexistence of factor V Leiden and factor II A20210 mutations and recurrent venous thromboembolism
33. The risk of recurrent venous thromboembolism in carriers and non-carriers of the G1691A allele in the coagulation factor V gene and the G20210A allele in the prothrombin gene
34. Clinical features in 36 patients homozygous for the ARG 506→GLN factor V mutation
35. If nothing goes wrong, is everything all right? Interpreting zero numerators
36. A reevaluation of the risk for venous thromboembolism with the use of oral contraceptives and hormone replacement therapy
37. Risk of venous thrombosis with use of current low-dose oral contraceptives is not explained by diagnosis suspicion and referral bias
38. Resistance to activated protein C in an unselected population of patients with pulmonary embolism
39. Low prevalence of FV:Q506 in 41 patients with isolated pulmonary embolism
40. Risk factor profiles in patients with different clinical manifestations of venous thromboembolism: A focus on the FV Leiden mutation
41. Is the prevalence of the factor V Leiden mutation in patients with pulmonary embolism and deep vein thrombosis really different?
42. Factors V Leiden and II 20210A allele in patients with symptomatic pulmonary embolism and deep vein thrombosis
43. Location and extent of deep vein thrombosis in patients with and without FV:R506Q mutation
44. Meta-analysis of observational studies in epidemiology. A proposal for reporting